BRPI9814499B8 - Synthetic opioid amide peptide or a pharmaceutically acceptable salt thereof, and pharmaceutical composition - Google Patents
Synthetic opioid amide peptide or a pharmaceutically acceptable salt thereof, and pharmaceutical compositionInfo
- Publication number
- BRPI9814499B8 BRPI9814499B8 BRPI9814499A BRPI9814499A BRPI9814499B8 BR PI9814499 B8 BRPI9814499 B8 BR PI9814499B8 BR PI9814499 A BRPI9814499 A BR PI9814499A BR PI9814499 A BRPI9814499 A BR PI9814499A BR PI9814499 B8 BRPI9814499 B8 BR PI9814499B8
- Authority
- BR
- Brazil
- Prior art keywords
- phe
- nle
- arg
- morpholinyl
- leu
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 abstract 1
- 102000051367 mu Opioid Receptors Human genes 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108020001588 κ-opioid receptors Proteins 0.000 abstract 1
- 108020001612 μ-opioid receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"peptídeo amida opióide sintético ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, processo para tratamento compreendendo a administração de uma quantidade da mesma". peptídeos que demonstram alta seletividade para o receptor opióide kappa (kor) e longa duração de ação periférica sem entrada significante no cerébro são criados que são seqüências de quatro resíduos de aminoácidos d-isômero tendo um c-término que é uma amida mono- ou disubstituída. os compostos representativos, que tem uma afinidade para o kor de pelo menos 1000 vezes sua afinidade para o receptor opióide mu e um ed~ 50~ não maior que cerca de 0,5 mg/kg, incluem h-d-phe-d-phe-d-nle-d-arg-nhet, h-d-phe-d-phe-d-nle-d-arg-morfolinila, h-d-phe-d-phe-d-nle-d-arg-nh-4-picolila, h-d-phe-d-phe-d-nle-d-arg-nhpr,h-d-phe-d-phe-d-nle-d-arg-tiomorfolinila, h-d-phe-d-phe-d-nle-d-arg-net~ 2~, h-d-phe-d-phe-d-nle-d-arg-nhme, h-d-phe-d-phe-d-nle-d-orn-morfolinila, h-d-4fpa-d-phe-d-nle-d-arg-nh-4-picolila, h-d-phe-d-phe-d-nle-d-arg-nh-ciclopropila, h-d-ala(2thi)d-3,4-cpa-d-leu-d-arg-morfolinila, h-d-phe-d-phe-d-nle-d-gmf-morfolinila, h-d-phe-d-phe-d-leu-d-orn-nh (aeb), h-d-phe-d-phe-d-leu-d-lys-morfolinila, h-d-phe-d-phe-d-nle-d-arg-piperazinila, e h-d-phe-d-phe-d-nle-d-arg-nh(hoh)."synthetic opioid amide peptide or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and, process for treatment comprising administering an amount thereof". peptides that demonstrate high selectivity for the kappa opioid receptor (kor) and long duration of peripheral action without significant entry into the brain are created that are sequences of four d-isomer amino acid residues having a c-terminus that is a mono- or disubstituted amide . representative compounds, which have an affinity for kor of at least 1000 times its affinity for the mu opioid receptor and an d~50~ not greater than about 0.5 mg/kg, include h-d-phe-d-phe- d-nle-d-arg-nhet, h-d-phe-d-phe-d-nle-d-arg-morpholinyl, h-d-phe-d-phe-d-nle-d-arg-nh-4-picolyl, h-d-phe-d-phe-d-nle-d-arg-nhpr,h-d-phe-d-phe-d-nle-d-arg-thiomorpholinyl, h-d-phe-d-phe-d-nle-d- arg-net~ 2~, h-d-phe-d-phe-d-nle-d-arg-nhme, h-d-phe-d-phe-d-nle-d-orn-morpholinyl, h-d-4fpa-d-phe -d-nle-d-arg-nh-4-picolyl, h-d-phe-d-phe-d-nle-d-arg-nh-cyclopropyl, h-d-ala(2thi)d-3,4-cpa-d -leu-d-arg-morpholinyl, h-d-phe-d-phe-d-nle-d-gmf-morpholinyl, h-d-phe-d-phe-d-leu-d-orn-nh (aeb), h-d- phe-d-phe-d-leu-d-lys-morpholinyl, h-d-phe-d-phe-d-nle-d-arg-piperazinyl, and h-d-phe-d-phe-d-nle-d-arg -nh(hoh).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/997,208 US5965701A (en) | 1997-12-23 | 1997-12-23 | Kappa receptor opioid peptides |
| PCT/US1998/027282 WO1999032510A1 (en) | 1997-12-23 | 1998-12-22 | Kappa receptor opioid peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI9814499A BRPI9814499A (en) | 2000-10-10 |
| BRPI9814499B1 BRPI9814499B1 (en) | 2014-10-21 |
| BRPI9814499B8 true BRPI9814499B8 (en) | 2021-11-09 |
Family
ID=25543752
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9814499-5A BR9814499B1 (en) | 1997-12-23 | 1998-12-22 | SYNTHETIC OPIOID PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, AND PHARMACEUTICAL COMPOSITION |
| BRPI9814499A BRPI9814499B8 (en) | 1997-12-23 | 1998-12-22 | Synthetic opioid amide peptide or a pharmaceutically acceptable salt thereof, and pharmaceutical composition |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9814499-5A BR9814499B1 (en) | 1997-12-23 | 1998-12-22 | SYNTHETIC OPIOID PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, AND PHARMACEUTICAL COMPOSITION |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5965701A (en) |
| EP (1) | EP1042359B1 (en) |
| JP (1) | JP4275852B2 (en) |
| KR (1) | KR100629548B1 (en) |
| CN (1) | CN1154655C (en) |
| AR (1) | AR014167A1 (en) |
| AT (1) | ATE301670T1 (en) |
| AU (1) | AU747806B2 (en) |
| BR (2) | BR9814499B1 (en) |
| CA (1) | CA2315878C (en) |
| CR (1) | CR5936A (en) |
| CZ (1) | CZ297281B6 (en) |
| DE (1) | DE69831176T2 (en) |
| DK (1) | DK1042359T3 (en) |
| EE (1) | EE04440B1 (en) |
| ES (1) | ES2247735T3 (en) |
| HR (1) | HRP20000415B1 (en) |
| HU (1) | HU227640B1 (en) |
| IL (3) | IL136742A0 (en) |
| MY (1) | MY117542A (en) |
| NO (1) | NO327080B1 (en) |
| NZ (1) | NZ505183A (en) |
| PL (1) | PL195842B1 (en) |
| PT (1) | PT1042359E (en) |
| RU (1) | RU2217437C2 (en) |
| SK (1) | SK286135B6 (en) |
| TR (1) | TR200001985T2 (en) |
| TW (1) | TW580502B (en) |
| UA (1) | UA68366C2 (en) |
| UY (1) | UY25327A1 (en) |
| WO (1) | WO1999032510A1 (en) |
| ZA (1) | ZA9811801B (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| AU1623801A (en) * | 1999-11-19 | 2001-05-30 | Palatin Technologies, Inc. | Opioid metallopeptide compositions and methods |
| DE10116978A1 (en) | 2001-04-05 | 2002-10-10 | Merck Patent Gmbh | Kappa opiate agonists for the treatment of diseases of the bladder |
| JP4239592B2 (en) * | 2001-05-08 | 2009-03-18 | 東レ株式会社 | Sepsis treatment |
| WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
| PL1786784T3 (en) | 2004-08-20 | 2011-04-29 | Mannkind Corp | Catalysis of diketopiperazine synthesis |
| KR101644250B1 (en) | 2004-08-23 | 2016-07-29 | 맨카인드 코포레이션 | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
| CN104324362B (en) | 2005-09-14 | 2018-04-24 | 曼金德公司 | Method for preparation of drug based on improving affinity of the active agent to crystalline microparticle surfaces |
| IN2015DN00888A (en) | 2006-02-22 | 2015-07-10 | Mannkind Corp | |
| EP2040733A2 (en) * | 2006-05-26 | 2009-04-01 | Cara Therapeutics, Inc. | Method for elevating prolactin in mammals |
| CA2653077A1 (en) * | 2006-05-26 | 2007-12-06 | Cara Therapeutics, Inc. | N-oxides of kappa opioid receptor peptides |
| US8906859B2 (en) * | 2006-11-10 | 2014-12-09 | Cera Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
| US8236766B2 (en) * | 2006-11-10 | 2012-08-07 | Cara Therapeutics, Inc. | Uses of synthetic peptide amides |
| US7713937B2 (en) * | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
| US7842662B2 (en) | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
| RU2500685C2 (en) | 2006-11-10 | 2013-12-10 | Кара Терапеутикс, Инк | Synthetic peptide amides |
| WO2008077194A1 (en) * | 2006-12-22 | 2008-07-03 | Xenome Ltd | Receptor agonists |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| ES2929343T3 (en) | 2008-06-13 | 2022-11-28 | Mannkind Corp | Suction Actuated Dry Powder Inhaler for Drug Delivery |
| KR101628410B1 (en) | 2008-06-20 | 2016-06-08 | 맨카인드 코포레이션 | An interactive apparatus and method for real-time profiling of inhalation efforts |
| TWI614024B (en) | 2008-08-11 | 2018-02-11 | 曼凱公司 | Ultra-fast use of insulin |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| DK2405963T3 (en) | 2009-03-11 | 2013-12-16 | Mannkind Corp | DEVICE, SYSTEM AND PROCEDURE FOR MEASURING RESISTANCE IN AN INHALATOR |
| CN104721825B (en) | 2009-06-12 | 2019-04-12 | 曼金德公司 | With the diketopiperazine particle for determining specific surface area |
| WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| IL223742A (en) | 2010-06-21 | 2016-06-30 | Mannkind Corp | Dry powder inhaler and composition therefor |
| AU2012236150B2 (en) | 2011-04-01 | 2016-03-31 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| BR112014009686A2 (en) | 2011-10-24 | 2018-08-07 | Mannkind Corp | Inhalable analgesic composition, dry powder and method for treating pain |
| CN104619369B (en) | 2012-07-12 | 2018-01-30 | 曼金德公司 | Dry powder drug delivery systems and methods |
| US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
| AU2014228415B2 (en) | 2013-03-15 | 2018-08-09 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| MX375448B (en) | 2013-07-18 | 2025-03-06 | Mannkind Corp | HEAT-STABLE DRY POWDER PHARMACEUTICAL COMPOSITIONS AND METHODS. |
| US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| JP5807140B1 (en) * | 2014-06-26 | 2015-11-10 | 積水メディカル株式会社 | Method for producing synthetic pentapeptide |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| EP3294315A2 (en) * | 2015-05-11 | 2018-03-21 | Cadila Healthcare Limited | Novel short-chain peptides as kappa opioid receptors (kor) agonist |
| CN107098876B (en) * | 2016-02-23 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | Phenyl propionamide derivative, preparation method and medical application thereof |
| CN109563133B (en) * | 2016-09-27 | 2020-09-11 | 四川科伦博泰生物医药股份有限公司 | Polyamide compounds and their uses |
| CA3069820C (en) * | 2017-07-21 | 2022-12-06 | Sichuan Haisco Pharmaceutical Co., Ltd. | Peptide amide compounds, preparation method thereof and use in medicine |
| MX2020005932A (en) | 2017-12-06 | 2020-08-24 | Jiangsu Hengrui Medicine Co | Salt of phenylpropionamide derivative and preparation method therefor. |
| CN111148526B (en) | 2018-05-16 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition of KOR receptor agonist |
| WO2021013085A1 (en) * | 2019-07-25 | 2021-01-28 | 四川海思科制药有限公司 | Peptide amide salt, preparation method therefor and use thereof in medicine |
| CN114127086B (en) * | 2019-07-25 | 2023-10-20 | 四川海思科制药有限公司 | Deuterated peptide amide compounds and their preparation methods and medicinal uses |
| WO2021026492A1 (en) * | 2019-08-07 | 2021-02-11 | Humanwell Pharmaceutical US | Kappa opioid receptor peptide amide agonists |
| EP4175944A4 (en) | 2020-06-25 | 2024-03-06 | Humanwell Pharmaceutical US | PEPTIDES FOR THE TREATMENT OF MEDICAL DISEASES |
| US20240336565A1 (en) | 2021-07-02 | 2024-10-10 | Acer Therapeutics, Inc. | Solid forms of osanetant |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2013689B (en) * | 1977-12-15 | 1982-03-24 | Reckitt & Colmann Prod Ltd | Compounds |
| GB8801304D0 (en) * | 1988-01-21 | 1988-02-17 | Ici Plc | Diamine compounds |
| US5367053A (en) * | 1993-05-19 | 1994-11-22 | Houghten Pharmaceuticals, Inc. | Opioid peptide inhibitors |
| RU2067000C1 (en) * | 1994-06-29 | 1996-09-27 | Владислав Исакович Дейгин | Peptide and a method of its synthesis |
| US5610271A (en) * | 1995-06-07 | 1997-03-11 | Torrey Pines Institute For Molecular Studies | Kappa receptor selective opioid peptides |
-
1997
- 1997-12-23 US US08/997,208 patent/US5965701A/en not_active Expired - Lifetime
-
1998
- 1998-12-22 UA UA2000063810A patent/UA68366C2/en unknown
- 1998-12-22 ES ES98964224T patent/ES2247735T3/en not_active Expired - Lifetime
- 1998-12-22 AT AT98964224T patent/ATE301670T1/en active
- 1998-12-22 SK SK960-2000A patent/SK286135B6/en not_active IP Right Cessation
- 1998-12-22 EE EEP200000370A patent/EE04440B1/en not_active IP Right Cessation
- 1998-12-22 IL IL13674298A patent/IL136742A0/en active IP Right Grant
- 1998-12-22 BR BRPI9814499-5A patent/BR9814499B1/en not_active IP Right Cessation
- 1998-12-22 WO PCT/US1998/027282 patent/WO1999032510A1/en not_active Ceased
- 1998-12-22 ZA ZA9811801A patent/ZA9811801B/en unknown
- 1998-12-22 NZ NZ505183A patent/NZ505183A/en not_active IP Right Cessation
- 1998-12-22 DK DK98964224T patent/DK1042359T3/en active
- 1998-12-22 MY MYPI98005818A patent/MY117542A/en unknown
- 1998-12-22 CZ CZ20002382A patent/CZ297281B6/en not_active IP Right Cessation
- 1998-12-22 PL PL98341308A patent/PL195842B1/en not_active IP Right Cessation
- 1998-12-22 BR BRPI9814499A patent/BRPI9814499B8/en unknown
- 1998-12-22 AU AU19402/99A patent/AU747806B2/en not_active Ceased
- 1998-12-22 KR KR1020007006936A patent/KR100629548B1/en not_active Expired - Lifetime
- 1998-12-22 TR TR2000/01985T patent/TR200001985T2/en unknown
- 1998-12-22 CN CNB98812582XA patent/CN1154655C/en not_active Expired - Lifetime
- 1998-12-22 CA CA2315878A patent/CA2315878C/en not_active Expired - Lifetime
- 1998-12-22 JP JP2000525447A patent/JP4275852B2/en not_active Expired - Lifetime
- 1998-12-22 PT PT98964224T patent/PT1042359E/en unknown
- 1998-12-22 HU HU0100626A patent/HU227640B1/en not_active IP Right Cessation
- 1998-12-22 HR HR20000415A patent/HRP20000415B1/en not_active IP Right Cessation
- 1998-12-22 EP EP98964224A patent/EP1042359B1/en not_active Expired - Lifetime
- 1998-12-22 DE DE69831176T patent/DE69831176T2/en not_active Expired - Lifetime
- 1998-12-22 CR CR5936A patent/CR5936A/en unknown
- 1998-12-22 RU RU2000119773/04A patent/RU2217437C2/en active
- 1998-12-23 UY UY25327A patent/UY25327A1/en unknown
- 1998-12-23 AR ARP980106652A patent/AR014167A1/en active IP Right Grant
-
1999
- 1999-02-10 TW TW087121390A patent/TW580502B/en not_active IP Right Cessation
-
2000
- 2000-06-12 IL IL136742A patent/IL136742A/en not_active IP Right Cessation
- 2000-06-21 NO NO20003245A patent/NO327080B1/en not_active IP Right Cessation
-
2006
- 2006-10-05 IL IL178471A patent/IL178471A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI9814499B8 (en) | Synthetic opioid amide peptide or a pharmaceutically acceptable salt thereof, and pharmaceutical composition | |
| Veber et al. | The design of metabolically-stable peptide analogs | |
| ATE384077T1 (en) | STEREOSELECTIVE ANTIFIBRILOGENIC PEPTIDES | |
| JP3347332B2 (en) | Inhibition of 26S and 20S proteasomes by indanone | |
| HUP0000492A1 (en) | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | |
| Chen et al. | Structure–bioactivity of C‐terminal pentapeptide of osteogenic growth peptide [OGP (10–14)] | |
| MX9703643A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein. | |
| Medeiros et al. | Metabolism and functions of neuropeptide Y | |
| CA2284547A1 (en) | Mu-opiate receptor peptides | |
| BR9714358A (en) | Derivatives of n- (aryl / heteroaryl) amino acid, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| US9447145B2 (en) | Compositions for inhibiting immune complex formation in a subject | |
| WO2002005748A3 (en) | Medicinal uses of mu-opioid receptor agonists | |
| CA2550085A1 (en) | Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders | |
| WO1996028470A3 (en) | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis | |
| MX9703642A (en) | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein. | |
| US5840697A (en) | Peptide inhibitors of calmodulin | |
| US6916904B2 (en) | Inhibition of immune complex formation | |
| Hasenöhrl et al. | Evidence for dose-dependent positively and negatively reinforcing effects of the substance P C-terminal analog DIME-C7 | |
| RU2264823C2 (en) | Method and peptides for treating erectile dysfunction, method and pharmaceutical composition at applying peptides mentioned | |
| US20080200392A1 (en) | Methods for Treating Parkinson's Disease | |
| IL120503A0 (en) | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them | |
| AU719632B2 (en) | Contryphan peptides | |
| WO2007144979A1 (en) | Peptide derivative | |
| NO921595L (en) | SUPERACTIVE GRF ANALOGS |